On January 6, 2009, Summit Corporation plc announced that it had entered into an exclusive worldwide licensing agreement with the Swiss company Evolva Biotech SA.
The agreement covers SMT 14400, a second-generation imino sugar, which is being developed as a potential treatment for infectious diseases associated with bioterrorism.
Allistair Booth and Stuart Richards of Fasken Martineau advised Summit Corporation in this matter.